## <sup>1</sup> External validation of prognostic and

# predictive gene signatures in head and neck cancer patients

#### 4

- 5 Erlend I. F. Fossen<sup>1,2,\*</sup>, Mauricio Moreira-Soares<sup>1</sup>, Marissa LeBlanc<sup>1,3</sup>, Arnoldo Frigessi<sup>1</sup>,
- 6 Eivind Hovig<sup>4,5</sup>, Laura Lopez-Perez<sup>6</sup>, Estefanía Estévez-Priego<sup>6</sup>, Liss Hernandez<sup>6</sup>, Maria
- 7 Fernanda Cabrera-Umpierrez<sup>6</sup>, Giuseppe Fico<sup>6</sup>, Ingeborg Tinhofer<sup>7</sup>, Vanessa Sachse<sup>7</sup>,
- 8 Kathrin Scheckenbach<sup>8</sup>, Christophe Le Tourneau<sup>9</sup>, Maud Kamal<sup>9</sup>, Steve Thomas<sup>10</sup>, Miranda
- 9 Pring<sup>10</sup>, Lisa Licitra<sup>11,12</sup>, Loris De Cecco<sup>13§</sup>, Stefano Cavalieri<sup>11,12§</sup>
- 10
- 11 <sup>1</sup>Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences,
- 12 University of Oslo, Oslo, Norway
- 13 <sup>2</sup> CICERO Center for International Climate Research, Oslo, Norway
- <sup>3</sup> Department of Method Development and Analytics, Norwegian Institute of Public Health,
   Oslo, Norway
- <sup>4</sup>Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
- <sup>5</sup> Department of Tumor biology, Institute for Cancer Research, Oslo University Hospital,
- 18 0310 Oslo, Norway
- <sup>6</sup> Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT,
   28040 Madrid, Spain
- <sup>7</sup> Department of Radiooncology and Radiotherapy, Translational Radiation Oncology
- 22 Research Laboratory, Charité Universitätsmedizin Berlin, corporate member of Freie
- 23 Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117 Berlin,
- 24 Germany
- 25 <sup>8</sup> Heinrich-Heine-Universität Düsseldorf, Dusseldorf, Germany
- <sup>9</sup> Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay
- 27 University, Paris, France
- 28 <sup>10</sup> Bristol Dental School, University of Bristol, United Kingdom
- 29 <sup>11</sup> Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei
- 30 Tumori di Milano, via Giacomo Venezian 1, 20133 Milan, Italy
- <sup>12</sup> Department of Oncology and Hemato-oncology, University of Milan, via Santa Sofia 9/1,
   20122 Milan, Italy
- <sup>13</sup> Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Giacomo
- 34 Venezian 1, 20133 Milan, Italy
- 35
- 36 \*Corresponding author, <u>erlend.fossen@cicero.oslo.no</u>
- 37 § Stefano Cavalieri and Loris De Cecco equally contributed as co-last authors.
- 38
- 39

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract 40

Head and neck squamous cell carcinomas (HNSCC) are aggressive and heterogenous tumors 41

with a high fatality rate. Many gene signatures (GS) have been developed with both 42

prognostic and predictive significance. We aimed to externally validate five published GS in 43

a large European collection of HNSCC patients. Gene expression from 1097 treatment-naïve 44

HNSCC patients' primary tumors was used to calculate scores for the five GS. Cox 45

proportional hazard models were used to test the association between both 2-year overall 46

survival and 2-year disease-free survival and the signature scores. The predictive role of GS 47

48 was validated by comparing survival associations in patients receiving specific treatment (i.e.,

radiotherapy, systemic treatment) versus those who did not. We successfully externally 49

50 validated all 5 GS, including two prognostic signatures, one signature as prognostic and 51 predictive of sensitivity to systemic treatment, while signatures for cisplatin-sensitivity and

radiosensitivity were validated as prognostic only. 52

53

#### 1. Introduction 54

Head and neck cancer (HNC) is the 7<sup>th</sup> most common cancer worldwide, with more than 55 890,000 new cases and 450,000 deaths annually<sup>1,2</sup>. Head and neck squamous cell carcinoma 56 (HNSCC) is the most common histological type of HNC, making up 90% of all HNC 57 58 cases<sup>2,3</sup>, roughly 4.5% of all global cancer diagnoses and approximately 4.6% of all cancer deaths<sup>1,2</sup>. Major risk factors for HNSCC are tobacco smoking and alcohol consumption<sup>1,3</sup>, but 59 human papillomavirus (HPV) infection is also a known risk factor for oropharyngeal 60

cancers<sup>4</sup>. 61

62

HNSCCs are a heterogenous group of cancers with malignancies developing at various 63

anatomical sub-sites and with high molecular tumor heterogeneity<sup>5,6</sup>. This heterogeneity 64

contributes to differences between patients in terms of treatment response with a need for 65

personalized approaches<sup>6,7</sup>. In general, HNSCC patients with early disease (stage I-II) have 66

high cure rates with single modality therapies (either surgery or radiotherapy). Subjects with 67 loco-regionally advanced disease (stage III-IVa/b) are treated with multimodal approaches

68 (i.e., various combinations of surgery, radiotherapy and systemic treatment)<sup>8</sup>. Despite optimal 69

treatments, approximately half of patients develop recurrence within 2 years and half die with 70

disease within 5 years from the diagnosis<sup>9</sup>. Reliable biomarkers and gene signatures (GS) are 71

crucial for developing personalized treatment<sup>10,11</sup>. GS are sets of genes involved in a 72

biological process that can provide information about the expected disease outcome 73

(prognostic) and/or the response to a specific treatment (predictive)<sup>10,11</sup>. Prognostic signatures 74

provide information about disease prognosis irrespective of therapy. Meanwhile, predictive 75

signatures inform about how likely a patient is to respond to a specific therapy and can 76

- 77 therefore enable more personalized treatment plans.
- 78

Many prognostic GS, calculated from gene expression in treatment-naïve tumors, have been 79

developed for HNSCC<sup>12-16</sup>. External validation of already published GS is an important step 80

towards incorporating GS in clinical practice<sup>17</sup>. In this study, we decided to consider only GS 81

which were already published, and which were either disease- or treatment-specific. Among 82

them is a 172-gene signature<sup>18</sup> (172-GS) that was developed to be prognostic of patient's risk 83

of relapse in HNSCC patients independently of HPV-status, but was later shown to not be 84 prognostic of overall survival (OS) in HPV-positive patients<sup>19</sup>. However, in the same patient 85 population, a specific three-cluster HPV signature<sup>20</sup> (3 clusters HPV) was developed and 86 externally validated as prognostic of OS<sup>19</sup>. As for predictive signatures, the 10-gene 87 radiosensitivity index<sup>21</sup> (RSI) is among the most validated pan-cancer GSs for prediction of 88 sensitivity to radiotherapy<sup>22</sup>. Another pan-cancer predictive signature, in this case predictive 89 of cisplatin-sensitivity<sup>23</sup> (pancancer-cisplatin), was recently developed, but has not been 90 externally validated in HNSCC patients. Lastly, a signature that classifies HNC patients into 91 six different subtypes/clusters was developed by De Cecco et al<sup>24</sup>. One of them (*Cl3-hypoxia*) 92 showed hypoxic features and was found to be prognostic<sup>19,25</sup> and related to response to 93 treatment with anti-EGFR agents (cetuximab and afatinib)<sup>26,27</sup>. 94 95 96 Using a large collection of HNSCC patients with available gene expression data, we aimed to externally validate two prognostic gene signatures (172-GS and 3 clusters HPV), two 97 predictive gene signatures (RSI and pancancer-cisplatin) and one prognostic and predictive 98 GS (*Cl3-hypoxia*). In contrast to earlier studies, we wanted to explicitly test whether the 99 100 prognostic signatures (172-GS and 3 clusters HPV) are valid independent of HPV-status, and explicitly test if the predictive signatures are predictive of treatment response by comparing if 101 the signature effect is only found in patients with a specific treatment and not in patients 102 without that treatment. We tested these signatures using two survival endpoints, OS and 103 disease-free survival (DFS). 104 105

#### 2. Methods 106

#### 2.1. Ethics statement 107

This study was conducted in full accordance with the World Medical Association's 108 Declaration of Helsinki (2013 version). The protocol was ethically approved by the 109 Norwegian Regional Committee for Medical and Health Research Ethics (REK) South-East 110 A under application number 270467. The data is securely stored in the University of Oslo's 111 112 server for sensitive data (TSD/USIT), adhering to the requirements of GDPR legislation. 113 Access to the data is granted only to authorized collaborators who have been included in the ethical approval. All proprietary studies that contributed data obtained ethical approval from 114 their respective local authorities in Italy, Germany, or France. Copies of these ethical 115 116 approvals were provided to the principal investigator by the data providers. BD2Decide was approved by the Ethical Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori 117 (Milan, Italy) in 2016 and it has two identifiers: INT65-16 and INT66-16. Biomarker analysis 118 of the ARO 04-01 Def-RCT cohort was approved by the Ethical Committee of the Charité -119 Universitätsmedizin Berlin (Berlin, Germany) in 2010 (EA2/086/10). Biomarker analysis of 120 the DKTKRO Def-RCT was approved by the Ethical Committee of the Technical University 121 of Dresden (Dresden, Germany) in 2014 (EK200112014). 122

123

#### 2.2. Patient selection 124

Within a European cooperative research project named SuPerTreat (research grant nr. 125 ERAPERMED2019-281, further details in Funding), we first identified and constructed a 126

127	multicenter dataset, which consisted primarily of data collected in previous research						
120	projects <sup>2</sup> (NC102832102, NC103017573, NC102059668) at the Fondazione IRCCS Istitute Nazionale dei Tumori (Milen, Italy), Institut Curie (Darie, France) and Charité						
129	Istituto Nazionale dei Tumori (Milan, Italy), Institut Curie (Paris, France) and Charite -						
121	Universital sine differentiation (Dermin, Germany) (Table S1 in supplementary information). We additionally included two nublic detects (TCC $\wedge$ 37.38 and CSE 4161239) that a there 1 to						
122	additionally included two public datasets ( $1 \cup GA^{3322}$ and $GSE41013^{322}$ ) that adhered to MIAME <sup>40</sup> and MINSEOE <sup>41</sup> standards						
122	IVITAIV						
127	The ce	lected studies complied with the following inclusion criteria:					
134	The se	sected studies complied with the following inclusion effectua.					
136	1	Diagnosis of head and neck squamous cell carcinoma (HNSCC)					
137	2	Planned treatment with curative intent					
120	2.	Tumor specimens (formalin-fixed paraffin-embedded FEPE) of HNSCC sampled					
120	5.	nrior to treatment, already assessed for gone expression analysis					
129	4	Stage L H, H, WA or WD according to the types and metastagic (TNIM) concer					
140	4.	Stage I, II, III, IVA of IVB according to the tumor-hode-metastasis (TINVI) cancer					
141	-	staging system /th edition <sup>2</sup>					
142	5.	One of the following tumor sites: oral cavity, oropharynx, hypopharynx, larynx					
143	6.	Age $\geq 18$ years					
144	A tota	l of $N = 1589$ patients were screened from these studies. From these, patients were					
145	exclud	led based on the following general exclusion criteria:					
146							
147	1.	Gene expression data not available					
148	2.	Distant metastasis at diagnosis or missing information about stage					
149	3.	Recurrent/metastatic disease at the time of study entry					
150	4.	Missing information about survival timing or survival status					
151							
152	Addit	ional exclusion criteria were applied when testing gene signatures related to					
153	sensiti	vity to systemic treatment:					
154	5.	Early disease stage excluded when testing signatures <i>pancancer-cisplatin</i> and <i>Cl3-</i>					
155		hypoxia. This specification is due to the fact that most early disease stage HNSCC					
156		patients are not treated with systemic treatment					
157	6.	Missing treatment information about systemic treatment agent when testing signatures					
158		pancancer-cisplatin and Cl3-hypoxia					
159							
160	A tota	l of 1097 patients were eligible for inclusion in this study, with the number reduced for					
161	gene s	ignatures related to sensitivity to systemic treatment (Figure 1, Table S1). In models					
162	testing the signatures 172-GS, 3 clusters HPV and RSI, all 1097 patients were eligible for						
163	analyzing OS (Figure 1) and 907 patients were eligible for DFS (Figure S1). In models						
164	testing sensitivity to systemic treatment signatures (pancancer-cisplatin and Cl3-hypoxia),						
165	750 patients were eligible for analyses of OS (Figure S2) and 700 patients were eligible for						
166	analys	es of DFS (Figure S3).					
16/	NT						
168	None	of the patients that were eligible for testing the signatures 1/2-GS, RSI, pancancer-					
120	cisplat	un or Cis-nypoxia were previously included in the development of these signatures. For shustons HDVGS most of the cligible HDV positive potients $(N = 152, 140/(25, 11))$					
171		custors $\Pi V$ GS, most of the engible $\Pi V$ -positive patients (N = 152, 14% of all a patients) were already part of a providue systemal validation of the signature <sup>19</sup> but in					
1/1 172	this st	e patients) were already part of a previous external validation of the signature <sup>25</sup> , but in					
172		and we additionally reside the OS III FIF v-negative patients and adjusted for more					
17/ 17/	covaria	aits.					
1/4							

#### 2.3. Endpoints, clinical variables and data harmonization 175

OS, defined as survival time from diagnosis until death of any cause or censoring, was 176 recorded in all studies. DFS, defined as time from diagnosis until cancer recurrence or death 177 of any cause, whichever occurred first, or censoring, was recorded in all but two studies 178 (Table S1). Patients were followed for up to 20 years in the period 1989-2017. Co-primary 179 180 endpoints were 2-year OS and 2-year DFS.

181

GSs were considered prognostic if they were associated with general disease prognosis 182

independently of treatments. We defined a GS as predictive if the prognostic capability was 183

limited to a population receiving a specific treatment. 184

185

Data harmonization of clinical variables was performed following head and neck ontology 186 (HeNeCOn<sup>43</sup>) and quality rules defined in BD2Decide study<sup>28</sup> (extended in the context of the 187

SuPerTreat project), to achieve comparable measurements across studies (see Table 1 and 188

Tables S2 and S3 for full list of clinical covariates). Tumor staging at diagnosis was 189

performed according to the 7th edition of the AJCC/UICC staging system<sup>42</sup>. The staging 190

variable was then classified in two main groups based on disease extension: early disease 191

(stage I-II) vs. loco-regionally advanced disease (stage III-IVa/b). Human papillomavirus 192

(HPV) infection is a known risk factor for oropharyngeal cancer<sup>4</sup> and HPV-status was 193

recorded for tumor tissues of all patients with oropharyngeal cancer, using either HPV 194 DNA/RNA tests (with DNA PCR or ISH with or without E6/E7 mRNA confirmation, as per 195

local guidelines) or through p16ink4a immunostaining. Non-oropharyngeal HNSCCs 196

(including oral cavity cancers<sup>44</sup>) were considered HPV-negative in analyses. Systemic 197

treatments were coded in two ways: 1) platinum-based (if carboplatin and/or cisplatin were 198

199 part of the agents a patient received) or non-platinum based (primarily cetuximab or

paclitaxel); and 2) cetuximab-based (if cetuximab was part of the agents a patient received) or 200 non-cetuximab based. Patients not receiving systemic treatments were in both cases coded as 201 such.

202 203

Treatments (surgery, radiotherapy and systemic therapy) performed with curative intent were 204 recorded as received or not received. This is potentially problematic since Cox regression 205 survival models assume that covariates are measured at baseline (diagnosis) or require 206 information about the timing of treatment. The use of the received treatment as a proxy for 207 intended treatment (a baseline covariate) may result in immortal time bias<sup>45</sup>. We performed 208 extensive sensitivity analyses to evaluate if our results were sensitive to using received 209 treatment as a covariate (Appendix 1). First, we considered the degree of mortality observed 210 during the period prior to when treatments were initiated. Second, we used an external dataset 211 (Head and Neck 5000<sup>46,47</sup>) with similar patient characteristics as SuPerTreat and compared 212 treatment coefficients from Cox models with either intended treatment or received treatment 213 214 as covariates. Third, we compared treatment coefficients from Cox models with received treatment with models where treatment was considered time-dependent (in a subset of 215 patients where the timing of surgery was known). Fourth, we used a landmark analysis<sup>48,49</sup> 216 and compared treatment coefficients from a Cox model with received treatment with a 217 218 landmark model where patients without an event or censoring prior to a landmark time point (corresponding with a time at which all patients started treatment) were followed from the 219 landmark time. Lastly, we used quantitative bias analyses<sup>50</sup> to compare estimates of received 220 treatments with bias-adjusted estimates of treatments. Based on these sensitivity analyses 221 (Results section 3.3.1), we inferred that our models are robust to violations of the 222 assumptions of the Cox regression models, and therefore used received treatment as a 223

covariate in our survival models. Although gene signatures are tested in interaction with 224 treatments, the tumor tissue used to obtain gene signature scores were sampled at diagnosis 225

(prior to treatment). 226

227

#### 2.4. Bioinformatics analysis 228

Gene expression data was profiled on different platforms depending on the study. Three 229 studies (study IDs: BD2 INT MI, BD2 UDUS, GSE41613) were profiled on Affymetrix 230 microarrays (platforms GPL23126 and GPL570), one study (GECO110) was profiled on 231 Illumina microarray (platform GPL14951), and two studies (SCANDARE, TCGA) were 232 profiled using Illumina RNA-seq. Within studies, Affymetrix data were quantile-normalized 233 using robust multi-array average (RMA). Illumina microarray data were quantile-normalized. 234 For RNA-seq data, within studies, we first removed very lowly expressed genes, where genes 235 were removed if all samples had < 0.25 counts per million (cpm), corresponding to max 5 236 reads in the smallest sample and max 22 reads in the largest sample. RNA-seq data were then 237 quantile-normalized using the limma R package<sup>51</sup> (function: voom). We used WGCNA 238 package<sup>52</sup> (function collapseRows and "maxRowVariance" method) to select the most 239 variable probe in cases when multiple probes mapped to the same EntrezID. Probes and 240 241 ensemble IDs that mapped to multiple EntrezID were removed. All gene expression data were log2-transformed after the abovementioned normalization. Genes that were missing for 242 all patients in a study were removed when combining datasets. ComBat<sup>53,54</sup> was used to 243 remove batch effects introduced by systemic non-biological technical errors from combining 244 data from multiple studies with different platforms. The largest proprietary study (ID: 245 BD2 INT MI) was used as reference in ComBat, parametric adjustment was performed, and 246 247 since there is variability in patient characteristics between studies, we only adjusted for the mean to not remove biological variance between the studies. To avoid bias in downstream 248 analyses<sup>55</sup>, we only included the batches (studies) as covariates in ComBat. 249

250

We calculated 5 gene signature scores for each patient following descriptions given in the 251 original publications (see Table S4 for detailed list of genes and weights per signature). The 252 signatures 172-GS<sup>18</sup>, 3 clusters HPV<sup>19,20</sup>, pancancer-cisplatin<sup>23</sup>, and Cl3-hypoxia<sup>24</sup> were 253 calculated as weighed sums using the equation: Gene signature score =  $\sum_{i=1}^{n} \beta_i \times Exp_i$ , 254 where  $\beta_i$  is the weight of the i-th gene (of n genes) and  $Exp_i$  is the gene expression of the i-th 255 gene. The 172-GS signature was calculated using the hacksig package<sup>56</sup>. The radiosensitivity 256 index (RSI) signature is based on the expression of 10 specific genes. RSI was calculated as a 257 weighed ranked sum using the equation:  $RSI = \sum_{i=1}^{10} \beta_i \times Ranked_Exp_i$ , where  $\beta_i$  is the 258 weight of the *i*-th gene and *Ranked* Exp<sub>i</sub> is the ranked gene expression of the *i*-th gene. For 259 each patient the 10 genes were ranked in ascending order using patient-specific expression 260 data, where the gene with the lowest expression is assigned a value of 1, and the gene with 261 the highest expression is assigned a value of 10. 262

263

Each gene signature was mean-centered and scaled by the standard deviation (SD) within its 264 265 respective dataset to make the scores easier to interpret (mean = 0, SD = 1, see Appendix 2

for means and SD on original scale). In our OS dataset, 76% of the 172-GS signature genes 266

were present, 46% of the 3 clusters HPV signature genes were present, all RSI genes were 267

present, 92% of the pancancer-cisplatin genes were present, and 94% of the Cl3-hypoxia 268

genes were present. For our DFS dataset, the presence of genes was 80% for the 172-GS 269

signature, 57% for the 3 clusters HPV signature, all RSI genes present, 92% for pancancer-270

cisplatin and 94% for Cl3-hypoxia genes (see Appendix 2 for a list of missing genes per gene 271 signature). Any missing genes were missing for all individuals, making regression-based 272 imputation not a viable option. Instead, all missing genes were imputed as having zero 273 expression. Note that the scaled signature values do not change if we instead were to impute 274

with another constant (e.g., imputing the overall mean expression). 275

276

#### **2.5.** Statistical analyses 277

- All statistical analyses were performed in R Statistical Software<sup>57</sup> (v4.1.3). 278
- 279

#### 2.5.1. Handling of missing clinical covariates 280

There were missing data in several categorical variables: smoking status, tumor stage and 281 received treatments (i.e., surgery, systemic therapy and radiotherapy). The missingness was 282 largely structural, resulting from some variables not being measured in some of the studies, 283 and therefore regression-based imputation of missing data was not a viable option<sup>58</sup>. Instead. 284 we used a missing indicator where missing values were coded as belonging to a "missing" 285 category (see Table 1 for amounts of missingness). 286 287

#### 2.5.2. Clinical base models 288

Clinical base models, i.e., those not including the gene expression data, were built as 289 benchmark models for models which included gene signatures as covariates. Four Cox 290 291 proportional hazard models were fit with either 2-year OS or 2-year DFS as endpoints. Two models were fit with the same data used to test signatures not related to sensitivity to 292 systemic treatment (172-GS, 3 clusters HPV and RSI) and two models were fit with the same 293 data used to test signatures related to sensitivity to platinum-based or cetuximab-based 294 treatments (pancancer-cisplatin and Cl3-hypoxia, respectively). In all models, age, sex, 295 296 tumor region and HPV-status, smoking status, undergone surgery (yes/no), received radiotherapy (yes/no), and study ID were used as covariates. In models testing signatures not 297 298 related to systemic treatment, disease extension (early stage, locoregionally advanced) and 299 received systemic therapy (yes/no) were also used as covariates. In models testing signatures 300 related to systemic treatment, TNM stage and a variable for systemic treatment (platinumbased version when testing pancancer-cisplatin; cetuximab-based version when testing Cl3-301 hypoxia) were included as covariates. The concordance index (Harrell's C-index<sup>59</sup>) was 302 303 calculated for each model to compare their discriminatory ability with the ability of models that included gene signatures (but see Hartman et al.<sup>60</sup> for limitations on interpreting the C-304 index). Additionally, we calculated each models measure of explained variation  $(R^2)$  as 305 defined by Royston<sup>61</sup> and building on previous work<sup>62,63</sup>. This measure is similar to R<sup>2</sup> of 306

linear models but was made for models analyzing censored survival data<sup>61</sup>. 307

#### 2.5.3. Gene signature validation models 308

309 To validate prognostic gene signatures (172-GS and 3 clusters HPV), we fit Cox proportional

hazard models where we tested if the gene signature was associated with survival endpoints 310

while adjusting for other covariates. For each GS, we used the same endpoints and covariates 311

medRxiv preprint doi: https://doi.org/10.1101/2024.09.24.24314278; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license.

as in the clinical base models, but also tested for an interaction between HPV-status and the 312

- GS. This allowed us to test if the same association between survival and GSs was found in 313
- both HPV-positive and in HPV-negative patients. 314

315 To validate predictive gene signatures (RSI, pancancer-cisplatin and Cl3-hypoxia), we fit 316 Cox proportional hazard models where we tested if gene signatures were associated with 317 survival endpoints and if there was evidence that gene signatures modified the effect of the 318 treatments (i.e., testing for an interaction between gene signatures and treatments). Finding a 319 significant interaction where a GS is associated with survival in a specific treatment but not 320 in others would imply that the signature is predictive. For validating each GS, we used the 321 same covariates as in the clinical base models, but also included relevant interactions between 322 GS and treatments. An interaction between radiotherapy and RSI was included when 323 324 validating RSI. For validation of the pancancer-cisplatin signature, we included an interaction between the *pancancer-cisplatin* signature and systemic treatment. Similarly for 325 validation of Cl3-hypoxia, we included an interaction between the Cl3-hypoxia signature and 326 systemic treatment (see Appendix 3 for formulas for each GS model). 327 328 To test the proportional hazard assumption of our Cox models, we performed sensitivity 329 analyses where we fit equivalent models as described above, using 5-year survival (both for 330 331 OS and DFS) as the endpoint instead of 2-year survival. We additionally estimated the

- median follow-up time using the reverse Kaplan-Meier method<sup>64</sup>. 332
- 333

#### 3. Results 334

#### **3.1.** Cohort characteristics 335

The largest dataset used for overall survival analyses, representing the full SuPerTreat cohort, 336 contained patients from 6 studies, where 67% of patients were from the two largest studies 337 (Table 1). The majority of patients were men (72%) and the cohort had a median age at 338 diagnosis of 61 years (SD = 12). Most patients had loco-regionally advanced disease (85%) 339 and underwent surgery (78%) and/or radiotherapy treatment (69%), with 42% of patients 340 341 receiving systemic treatment. There was heterogeneity in tumor regions, and the most frequent primary site was oral cavity (55%) (Table 1). Similar cohort characteristics were 342 observed in the dataset used for disease-free survival (Table 1), and in subsets of patients that 343 344 were used to test the effect of other GSs on survival endpoints (Tables S2, S3). Among patients who received systemic treatment with information available about the therapeutic 345 agent, 87.6% received platinum-based and 8.5% received cetuximab-based therapies (Table 346 S3). 347

#### 3.2. Gene signatures 348

#### 3.2.1. Prognostic signature: 172-GS 349

The 172-GS signature was significantly associated with 2-year OS in HPV-negative patients, 350 where increasing the signature score by 1 (representing an increase of 1 standard deviation) 351 352 resulted in 41% higher hazard (HR = 1.41 [CI: 1.25, 1.59], Table 2, Figure 2). No evidence of an interaction between the signature score and HPV-status was found (p = 0.621), indicating 353 that the association between survival and the GS was similar in HPV-positive patients (HR =354 1.87 [CI: 0.61, 5.78], Table 2). However, the score was not significantly associated with OS 355

in HPV-positive patients when testing the marginal effect of the signature conditioned on 356 being HPV-positive (Table 2). When fixing the signature score at zero (representing the mean 357 score), HPV-negative patients had a 4.27-fold higher hazard than HPV-positive patients 358 (Table 2). The models C-index was 0.71 (SE = 0.02) and  $R^2 = 0.29$ . The C-index of the 359 corresponding clinical base model (i.e. not including the GS as a covariate) was 0.69 (SE = 360 0.02) and  $R^2 = 0.23$ . 361

362

Similar effect sizes and significance levels were found for 2-year DFS, with a significant 363 association between the signature score and survival in HPV-negative patients (HR = 1.36 364 [CI: 1.17, 1.59], Table 2). There was no evidence of an interaction between the signature 365 score and HPV-status (p = 0.651), and the score was not significantly associated with DFS in 366 HPV-positive patients when conditioned on being HPV-positive (Table 2). The models C-367 index was 0.67 (SE = 0.02) and  $R^2 = 0.22$ . The corresponding clinical base model had a C-368 index of 0.66 (SE = 0.02) and  $R^2 = 0.18$ . See Table S5 for details about other covariates 369 included in the 172-GS models. 370

371

#### 3.2.2. Prognostic signature: 3 clusters HPV 372

There was a significant association between the 3 clusters HPV signature and 2-year OS in 373 HPV-positive patients, where increasing the signature score resulted in a lower hazard (HR = 374 375 0.41 [CI: 0.24, 0.71], Table 2, Figure 3). There was evidence of an interaction between the signature score and HPV-status (p = 0.007), indicating that the effect of the GS was different 376 in HPV-negative patients (HR = 0.89 [CI: 0.77, 1.02], Table 2). Moreover, the score was not 377 significantly associated with OS in HPV-negative patients (Table 2). These patients had a 378 4.17-fold higher hazard than HPV-positive patients when fixing the signature score at zero 379 (Table 2). The model had a  $R^2 = 0.25$  and C-index = 0.69 (SE = 0.02). The C-index of the 380 corresponding clinical base model was 0.69 (SE = 0.02) and R<sup>2</sup> = 0.23. 381

382

We found similar effect sizes and significance levels for 2-year DFS, with a significant 383 association between the GS and survival in HPV-positive patients (HR = 0.51 [CI: 0.33, 384 0.77], Table 2). Evidence of an interaction between the signature score and HPV-status was 385 also found (p = 0.001), and the score was not significantly associated with DFS in HPV-386 negative patients (Table 2). The models C-index was 0.67 (SE = 0.02) and  $R^2 = 0.20$ . The C-387 index of the corresponding clinical base model was 0.66 (SE = 0.02) and  $R^2 = 0.18$ . See 388 Table S6 for details about other covariates included in the 3 clusters HPV models. 389 390

#### 3.2.3. Predictive signature: radiosensitivity index (RSI) 391

The RSI was significantly associated with 2-year OS in patients receiving radiotherapy, 392 where a higher hazard was found when increasing the signature score (HR = 1.25 [CI: 1.08, 393 1.44], Table 2, Figure 4). We found no evidence of an interaction between *RSI* and 394 radiotherapy (p = 0.672), suggesting that the association between survival and RSI was the 395 same, although not significantly associated, in patients that did not receive radiotherapy (HR 396 397 = 1.17 [0.90, 1.52], Table 2, Figure 4). When RSI was set to zero, there was no significant association between survival and having received radiotherapy (Table 2). The models C-398 index was 0.70 (SE = 0.02) and  $R^2 = 0.25$ . The corresponding clinical base model had a C-399 index of 0.69 (SE = 0.02) and R<sup>2</sup> = 0.23. 400 401

In contrast to OS, there was no significant association between 2-year DFS and RSI (Table 2). 402 There was also no evidence of an interaction between RSI and having received radiotherapy 403 (p = 0.601). The models C-index was 0.66 (SE = 0.02) and R<sup>2</sup> = 0.18. The corresponding 404 clinical base models C-index was 0.66 (SE = 0.02) and  $R^2 = 0.18$ . See Table S7 for details 405 about other covariates included in the RSI models. 406

407

#### 3.2.4. Predictive signature: Pancancer-cisplatin 408

There was a significant association between the pancancer-cisplatin signature and 2-year OS 409 in patients receiving platinum-based chemotherapy, where a higher hazard was observed 410 when increasing the signature (HR = 1.29 [CI: 1.04, 1.59], Table 2, Figure 5). When 411 platinum-based chemotherapy was the reference, there was no evidence of interactions 412 between the signature and systemic treatment (p = 0.200 when compared to non-platinum 413 based, p = 0.908 when compared to no systemic therapy), suggesting that the association 414 415 between the signature and overall survival may be similar in these groups. However, there was no significant association between survival and the signature score when conditioning on 416 receiving non-platinum based systemic therapy or when not receiving systemic treatment 417 (Table 2, Figure 5). There was also no significant association between survival and systemic 418 treatment when the signature score was set to zero (Table 2). The models  $R^2 = 0.32$  and C-419 index was 0.72 (SE = 0.02). The corresponding clinical base model had a C-index of 0.71 420 (SE = 0.02) and  $R^2 = 0.30$ . 421

422

423 In contrast to OS, we found no significant association between 2-year DFS and the

424 pancancer-cisplatin signature (Table 2). There was also no evidence of interactions between

the score and systemic treatment when platinum-based chemotherapy was the reference (p =425

0.258 when compared to non-platinum based, p = 0.571 when compared to no systemic 426

treatment). The models C-index was 0.70 (SE = 0.02) and  $R^2 = 0.28$ . The C-index of the 427 corresponding clinical base model was 0.70 (SE = 0.02) and  $R^2 = 0.26$ . See Table S8 for 428

429 details about other covariates included in the pancancer-cisplatin models.

430

#### 3.2.5. Predictive and prognostic signature: Cl3-hypoxia 431

The *Cl3-hypoxia* signature was significantly associated with 2-year OS in patients receiving 432 non-cetuximab-based systemic treatments, where increasing the signature score resulted in a 433 lower hazard (HR = 0.69 [CI: 0.54, 0.87], Table 2, Figure 6). A similar, but non-significant, 434 association between OS and the GS was found for cetuximab-treated patients (HR = 0.67 [CI: 435 436 0.39, 1.14], Table 2, Figure 6). In contrast, an opposite association was found between OS and the signature in patients who did not receive systemic treatments, where higher signature 437 scores were associated with higher hazards (HR = 1.70 [CI: 1.12, 2.58], Table 2, Figure 6). 438 There was evidence of interactions between the signature and systemic treatment when using 439 440 no systemic treatment as the baseline (comparison with cetuximab group: p = 0.006; 441 comparison with non-cetuximab: p < 0.001), but no evidence of an interaction when comparing cetuximab-treated patients with patients receiving other types of systemic 442 443 treatment (p = 0.919). When the GS score was set to zero, there was no significant association between survival and systemic treatment (Table 2). The models C-index was 0.73 444 (SE = 0.02) and  $R^2 = 0.34$ . The C-index of the corresponding clinical base model (i.e. not 445 including the GS as a covariate) was 0.71 (SE = 0.02) and  $R^2 = 0.29$ . 446 447

- Similar effect sizes and significance levels were found when analyzing 2-year DFS (Table 2). 448
- Increasing the signature score was associated with a reduced hazard in patients receiving 449
- systemic treatment, while being significantly associated with an increased hazard in patients 450
- not receiving systemic treatments (Table 2). There was evidence of interactions between the 451 signature and systemic treatment when no systemic treatment was the baseline (comparison 452
- with cetuximab group: p = 0.006; comparison with non-cetuximab: p < 0.001), but no 453
- evidence of an interaction when comparing patients receiving cetuximab with patients 454
- receiving non-cetuximab therapies (p = 0.943). The models  $R^2 = 0.32$  and C-index = 0.71 (SE 455
- = 0.02). The C-index of the corresponding clinical base model was 0.70 (SE = 0.02) and  $R^2$  = 456
- 457 0.27. See Table S9 for details about other covariates included in the Cl3-hypoxia GS.
- 458

#### 3.3. Sensitivity analyses 459

#### 3.3.1. Coding of treatment 460

- We performed sensitivity analyses to evaluate the effect of using the received treatment as a 461 proxy of intended treatment (Appendix 1). Results of these analyses are summarized below: 462 463 i) All treated patients started treatment within 6 months after diagnosis, with most starting treatment within 3-4 months. In the first 6 months after diagnosis, the 464 mortality was approximately 3%. 465 We obtained overlapping and similar treatment coefficients when comparing ii) 466 intended and received treatment in an external dataset with similar patients' 467 characteristics. 468 We obtained overlapping and similar treatment coefficients when comparing iii) 469 received treatment with time-dependent treatment in a subset of patients where the 470 timing of surgery was known. 471 A landmark analysis showed overlapping and similar treatment coefficients as 472 iv) 473 when using received treatment. Quantitative bias analyses showed bias-adjusted estimates of treatment effects that 474 v) overlap with estimates obtained when using received treatment. 475 476
- 3.3.2. 5-year endpoints 477

Effect sizes and significance levels from models with 5-year OS and 5-year DFS were very 478 479 similar to the 2-year survival models (see Figures S4-S13 for forest plots and Tables S5-S9 for detailed results). The main difference was in the model of 5-year OS and the *Cl3-hypoxia* 480 signature, where there was no longer evidence of an association between the score and 481 survival in patients not receiving systemic treatments (HR = 1.43 [CI: 0.96, 2.13], p = 0.076). 482 Moreover, there was no longer evidence of an interaction between the score and systemic 483 treatment when comparing patients untreated with systemic agents with patients receiving 484 485 cetuximab (p = 0.068). The median follow-up time was 1325 days (approx. 3.63 years). 486

#### 4. Discussion 487

In this study, we externally validated five gene signatures using one of the world's largest 488 489 collections of HNSCC patients with available gene expression, harmonizing and combining

high quality clinical data from different studies. The development of this wide European 490 dataset has shown that the integration of multisource clinical and biological databases is 491 feasible. This successful integration is unprecedented and amplifies the knowledge about the 492 complexity and the heterogeneity of HNSCCs, contributing to their qualification and 493 quantification. The external validation ensures the robustness of the GSs and their potential 494 generalizability. In addition, tumor heterogeneity and complexity coupled with the variety of 495 treatment options imposes a biology-driven personalized approach in the curative setting of 496 HNSCC patients. Unlike more frequent tumors (e.g., breast cancer, non-small cell lung 497 cancer, or colorectal cancer), GSs have not been included yet either in clinical decision 498 making, or in clinical trial eligibility and stratification of HNSCC patients. 499

500

Except for the model testing associations between RSI and disease-free survival, all models 501 502 including gene signatures outperformed their corresponding clinical omics-free base models, as indicated by C-index and/or R<sup>2</sup>. Our results confirmed two potentially prognostic 503 signatures (172-GS and 3 clusters HPV) and validated one potentially prognostic/predictive 504 signature (*Cl3-hypoxia*) for cetuximab- and chemosensitivity. However, the results for two 505 506 potentially predictive signatures (RSI and pancancer-cisplatin) were less conclusive, despite showing associations with overall survival in patients receiving radiotherapy or platinum-507 based chemotherapy. 508

509

The signature  $172-GS^{18}$  was validated as a prognostic indicator for both overall and disease-510 free survival in patients with HPV-unrelated disease. A higher signature score is associated 511 with a higher risk. The signature may also be prognostic in HPV-positive oropharyngeal 512

cancer patients, as given by the lack of evidence of an interaction between the signature and 513

HPV-status. This contrasts with previously published results<sup>19</sup>, possibly due to adjustments 514

515 for covariates and uncertainties in estimates of the signature effect for HPV-positive patients.

516

The 3 clusters HPV signature<sup>20</sup> was validated as prognostic for both OS and DFS in HPV-517

positive oropharyngeal cancer patients, consistent with a previous validation study<sup>19</sup>. 518

Additionally, there was no evidence of the signature being prognostic for HPV-negative 519

520 patients, suggesting its relevance specifically to HPV-positive oropharyngeal cancer.

521

In our study, we found a link between the radiosensitivity index  $(RSI)^{21}$  and overall survival 522

in patients who underwent radiotherapy, consistent with other studies<sup>18,19,22,65</sup>. However, we 523

- did not observe any interaction between RSI and radiotherapy. We also found a similar but 524
- 525 not significant association between RSI and OS in patients who did not receive radiotherapy.

This suggests that RSI may be more prognostic for survival than predictive of 526

radiosensitivity. This surprising finding of a prognostic effect of RSI in non-irradiated 527

patients may be because of the relatively low number of non-irradiated patients in our study. 528

In contrast to other studies<sup>22,66</sup>, we did not find a connection between *RSI* and DFS. 529

530

To our knowledge this is the first external validation of the *pancancer-cisplatin* signature<sup>23</sup> in 531

head and neck cancer patients. We found a negative association between the signature score 532

and overall survival (OS) in patients receiving platinum-based chemotherapy. Given that 533

534 higher GS scores were linked to higher cisplatin-sensitivity in the original publication<sup>23</sup>, our finding is in the opposite direction of what is expected. Additionally, we did not find

535 evidence of an interaction between systemic treatment and the signature. Due to an imbalance 536

537 in the number of patients with each type of systemic treatment, we could not draw definitive

conclusions about the potential prognostic or predictive effects of the signature. Lastly, we 538

found no associations between disease-free survival (DFS) and the pancancer-cisplatin 539

signature, suggesting that its predictive power may vary with clinical outcomes and not be 540 universal for all cancers. 541

542

In general, a GS is prognostic if it is able to forecast patient survival independently of the 543 received treatment. At the same time, if a prognostic GS is tested on a subset of patients 544 receiving curative therapies including a specific approach, then the prognostic performance 545 necessarily implies a certain predictive capability. In this scenario, the Cl3-hypoxia<sup>24</sup> 546 signature score was positively associated with both OS and DFS in patients receiving 547 systemic treatment but negatively associated with survival in subjects not receiving systemic 548 549 agents, suggesting the signature is predictive of sensitivity to systemic therapy. A similar positive association with survival endpoints was found in both cetuximab-treated patients and 550 in patients with chemotherapy, which did not include anti-EGFR agents. The association 551 between signature and survival is consistent with previous findings in HPV-positive 552 oropharyngeal cancer<sup>19</sup> and in oral premalignant lesions<sup>25</sup>. Previous studies have suggested 553 that the signature is related to cetuximab-sensitivity<sup>26,27</sup>, but our results indicate that it is 554 predictive of sensitivity to systemic treatment in general. 555

556

557 This study offers various opportunities for further improvement and refinement. Firstly, we used the received treatment as a proxy for intended treatment. While this breaks an 558 559 assumption of the Cox regression model, we performed extensive sensitivity analyses that suggest the models are robust to this violation. Secondly, 3-7% of patients (depending on the 560 model) were excluded for missing overall survival status or timing, and 6-19% were excluded 561 for missing DFS. This complete case exclusion reduced the sample sizes. Still, because the 562 missingness was primarily structural<sup>58</sup>, where the survival endpoint was missing for all 563 patients in a study, it is unlikely that it biased the results. Third, we used the missing indicator 564 565 method for missing covariates (with missingness ranging from 3-30% depending on the covariate), which can lead to biased results in non-randomized studies<sup>67</sup>, but is unlikely to 566 result in bias unless the covariate is a strong confounder or missing in extreme proportion 567 (>50% missing)<sup>68</sup>. Moreover, like the missingness in endpoints, the missingness in covariates 568 was primarily structural, and alternative regression-based imputation methods were therefore 569 not a viable option. Lastly, the imbalance in the number of patients with different treatments 570 (e.g., only 35 patients received cetuximab) made it difficult to precisely estimate interactions 571 and effects of gene signatures in small groups and made conclusions less clear. 572

573

We externally validated five gene signatures using a large integrated dataset of HNSCC 574

575 patients. Our results validated two prognostic signatures, 172-GS and 3 clusters HPV

signature, in HPV-negative patients and HPV-positive patients, respectively. We also 576

validated that the potentially predictive signatures RSI and pancancer-cisplatin were 577

578 prognostic of survival in patients with radiotherapy and platinum-based chemotherapy,

respectively, but could not conclude if these signatures are also predictive of radiosensitivity 579

or platinum-chemosensitivity. Lastly, we validated the Cl3-hypoxia signature as predictive of 580

- 581 sensitivity to systemic treatment, making this signature a good candidate for use in personalized treatment decisions. 582
  - 583

Many clinical studies aimed at intensifying $^{69-71}$  or de-escalating $^{72-74}$  standard treatments have 584 failed in head and neck oncology. A possible drawback could be the lack of an appropriate 585

patient selection, which may have hampered the opportunity to detect a signal of clinical 586

587 benefit with a given therapeutic approach. The significant biological differences in the

current study demonstrate the high heterogeneity of HNSCCs. Therefore, future clinical trials 588

should pursue a better patient selection that includes a broader use of GS and incorporates 589

them as inclusion criteria or stratification factors. In this scenario, the results of our external 590

- validation in one of the widest HNSCC datasets may be considered a historical benchmark 591 for the design of future studies. 592
- 593

#### Data availability 5. 594

The SuPerTreat dataset is hosted by the Services for Sensitive Data (TSD) at the University 595

of Oslo. Anonymized data containing only the survival endpoints and gene signature scores 596

will be uploaded to Zenodo prior to publication. Access to the original data may be granted 597 by the data owners upon application. 598

#### 6. Code availability 599

The underlying code (R scripts) used to analyse and validate gene signatures is available on 600 GitHub and can be accessed via this link

- 601
- https://github.com/erlendfossen/SuPerTreat GS validation. 602
- 603

#### 7. Acknowledgements 604

This work is part of the research project "Supporting Personalized Treatment Decisions in 605 Head and Neck Cancer through Big Data (SuPerTreat)" funded within ERA PerMed 606 JTC2019 Joint transnational call for proposals (2019) for "Personalised medicine: 607 multidisciplinary research Toward implementation", research grant nr. ERAPERMED2019-608 281 and supported by FRRB (Fondazione Regionale per la Ricerca Biomedica), BMBF 609 (Bundesministerium für Bildung und Forschung), RCN (Norges forskningsråd), ANR 610 (Agence nationale de la recherche) and GSRT (General Secretariat for Research and 611 Technology). MM-S received funding from the European Union's Horizon 2020 612 Research and Innovation program under the Marie Skłodowska-Curie Actions Grant, 613 agreement No. 80113 (Scientia fellowship). BD2Decide received funding from the European 614 Union Horizon 2020 Framework Programme, Grant/Award Number: 689715. We thank the 615 researchers, clinicians and other staff that designed and conducted the studies that this work 616 builds on. We also thank the head and neck cancer patients that took part in the studies. 617 618

#### **Author contributions** 8. 619

Conceptualization: E.I.F.F., M.M.S., M.L., A.F., I.T., C.L.T., L.L, L.D.C, S.C.; Data curation: 620 E.I.F.F., M.M.S., L.L.P, E.E.P, L.H, L.D.C, S.C.; Formal analysis: E.I.F.F., M.M.S., M.L., 621 A.F., L.D.C, S.C.; Funding acquisition: A.F., E.H., M.F.C.U, G.F., I.T., L.L.; Investigation: 622 623 I.T., V.S., K.S., C.L.T., M.K., S.T., M.P., L.L, L.D.C, S.C.; Methodology: E.I.F.F., M.M.S., M.L., A.F., L.L, L.D.C, S.C.; Resources: A.F., L.L.; Software: E.I.F.F., M.M.S.; Supervision: 624

M.L., A.F., M.F.C.U., G.F.; Visualization: E.I.F.F.; Writing-original draft: E.I.F.F.; Writing-625

review & editing: All authors. All authors approved the submission of this manuscript. L.D.C.and S.C. contributed equally to this work as co-last authors.

628

## **9. Competing interests**

630 M.L. reports receiving a speaker fee from MSD unrelated to the content of this work. L.L.

declares the following conflicts of interest, all unrelated to the content of this work: research

funds donated directly to the institute for clinical trials from AstraZeneca, BMS, Boehringer
 Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-

Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann
La Roche Ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche,

and Buran; occasional fees for participation as a speaker at conferences/congresses or as a

636 scientific consultant for advisory boards from AstraZeneca, Bayer, MSD, Merck-Serono,

637 AccMed, Neutron Therapeutics, Inc., and Alentis. S.C. declares occasional fees for

638 participation as a speaker at conferences/congresses from AccMed; support for attending

639 meetings and/or travel from AccMed, MultiMed Engineers srl, Care Insight sas, unrelated to

640 the content of this work. All remaining authors declare no competing interests.

### 642 References

- 1. Barsouk, A., Aluru, J. S., Rawla, P., Saginala, K. & Barsouk, A. Epidemiology, Risk Factors, and
- 644 Prevention of Head and Neck Squamous Cell Carcinoma. *Med. Sci.* **11**, 42 (2023).
- 645 2. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
- 646 Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **71**, 209–249 (2021).
- 3. Gormley, M., Creaney, G., Schache, A., Ingarfield, K. & Conway, D. I. Reviewing the epidemiology
- of head and neck cancer: definitions, trends and risk factors. *Br. Dent. J.* **233**, 780–786 (2022).
- 4. Sabatini, M. E. & Chiocca, S. Human papillomavirus as a driver of head and neck cancers. Br. J.
- 650 *Cancer* **122**, 306–314 (2020).
- 5. Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck
  cancer. *Nat. Rev. Cancer* 18, 269–282 (2018).
- 653 6. Mes, S. W., Leemans, C. R. & Brakenhoff, R. H. Applications of molecular diagnostics for
- personalized treatment of head and neck cancer: state of the art. *Expert Rev. Mol. Diagn.* 16,
  205–221 (2016).
- 656 7. Reid, P. *et al.* Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in
- 657 cancer stem cell heterogeneity, plasticity and treatment response. *Radiother. Oncol.* **135**, 1–12
- 658 (2019).
- 8. Machiels, J.-P. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and
- 660 hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and

661 follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. **31**, 1462–1475 (2020).

- 662 9. Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of
- 663 RARECAREnet—a population-based study. *Lancet Oncol.* **18**, 1022–1039 (2017).
- 10. Ballman, K. V. Biomarker: Predictive or Prognostic? J. Clin. Oncol. 33, 3968–3971 (2015).
- 11. Al-Tashi, Q. et al. Machine Learning Models for the Identification of Prognostic and Predictive
- 666 Cancer Biomarkers: A Systematic Review. Int. J. Mol. Sci. 24, 7781 (2023).

- 12. Huo, M. et al. Tumor microenvironment characterization in head and neck cancer identifies
- prognostic and immunotherapeutically relevant gene signatures. *Sci. Rep.* **10**, 11163 (2020).
- 13. Feng, B. & Hess, J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic
- 670 Value and Therapeutic Impact for Head and Neck Cancer. *Cancers* 13, 1162 (2021).
- 14. Wang, J. *et al.* Six-gene signature for predicting survival in patients with head and neck
- 672 squamous cell carcinoma. *Aging* **12**, 767–783 (2020).
- 15. Liu, B. et al. Prognostic Value of Eight-Gene Signature in Head and Neck Squamous Carcinoma.
- 674 Front. Oncol. **11**, (2021).
- 16. Tonella, L., Giannoccaro, M., Alfieri, S., Canevari, S. & De Cecco, L. Gene Expression Signatures
- 676 for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? *Curr.*
- 677 Treat. Options Oncol. 18, 32 (2017).
- 678 17. Steckler, A. & McLeroy, K. R. The Importance of External Validity. *Am. J. Public Health* **98**, 9–10
  679 (2008).
- 18. De Cecco, L., Bossi, P., Locati, L., Canevari, S. & Licitra, L. Comprehensive gene expression meta-
- 681 analysis of head and neck squamous cell carcinoma microarray data defines a robust survival
- 682 predictor. Ann. Oncol. 25, 1628–1635 (2014).
- 19. Cavalieri, S. *et al.* Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in
- 684 Human Papillomavirus–Positive Oropharyngeal Carcinoma. *JCO Precis. Oncol.* 1666–1676 (2021)
- 685 doi:10.1200/PO.21.00094.
- 686 20. Locati *et al.* Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic
- 687 Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. *Cancers* 11, 1057
  688 (2019).
- 088 (2019)
- Eschrich, S. A. *et al.* A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of
  Response and Prognosis After Chemoradiation. *Int. J. Radiat. Oncol.* **75**, 489–496 (2009).
- 691 22. Torres-Roca, J. F., Grass, G. D., Scott, J. G. & Eschrich, S. A. Towards Data Driven RT Prescription:
- 692 Integrating Genomics into RT Clinical Practice. *Semin. Radiat. Oncol.* **33**, 221–231 (2023).

- 693 23. Wells, J. D., Griffin, J. R. & Miller, T. W. Pan-Cancer Transcriptional Models Predicting
- 694 Chemosensitivity in Human Tumors. *Cancer Inform.* **20**, 117693512110024 (2021).
- 695 24. De Cecco, L. et al. Head and neck cancer subtypes with biological and clinical relevance: Meta-
- analysis of gene-expression data. *Oncotarget* **6**, 9627–9642 (2015).
- 697 25. Carenzo, A. *et al.* Gene Expression Clustering and Selected Head and Neck Cancer Gene
- 698 Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. Cells 9, 1828
- 699 (2020).
- 26. Bossi, P. et al. Functional Genomics Uncover the Biology behind the Responsiveness of Head and
- 701 Neck Squamous Cell Cancer Patients to Cetuximab. *Clin. Cancer Res.* 22, 3961–3970 (2016).
- 702 27. Lenoci, D. *et al.* Biological properties of hypoxia-related gene expression models/signatures on
- 703 clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity
- 704 trials. Oral Oncol. **126**, 105756 (2022).
- 28. Cavalieri, S. *et al.* Development of a multiomics database for personalized prognostic forecasting
- in head and neck cancer: The Big Data to Decide EU Project. *Head Neck* **43**, 601–612 (2021).
- 29. Sablin, M.-P. *et al.* Identification of new candidate therapeutic target genes in head and neck
- 708 squamous cell carcinomas. *Oncotarget* **7**, 47418–47430 (2016).
- 30. Neuzillet, C. et al. Prognostic value of intratumoral Fusobacterium nucleatum and association
- 710 with immune-related gene expression in oral squamous cell carcinoma patients. *Sci. Rep.* **11**,
- 711 7870 (2021).
- 712 31. Hoffmann, C. *et al.* MMP2 as an independent prognostic stratifier in oral cavity cancers.
- 713 *Oncoimmunology* **9**, 1754094 (2020).
- 32. Leblanc, O. *et al.* Biomarkers of cetuximab resistance in patients with head and neck squamous
- 715 cell carcinoma. *Cancer Biol. Med.* **17**, 208–217 (2020).
- 33. Lecerf, C. *et al.* Immune gene expression in head and neck squamous cell carcinoma patients.
- 717 *Eur. J. Cancer* **121**, 210–223 (2019).

- 718 34. Hoffmann, C. et al. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in
- cancer, allergy and autoimmunity. *Nat. Commun.* **13**, 1983 (2022).
- 35. Moreira, A. *et al.* Prognostic value of tumor mutational burden in patients with oral cavity
- squamous cell carcinoma treated with upfront surgery. *ESMO Open* **6**, 100178 (2021).
- 36. Karabajakian, A. et al. Longitudinal assessment of PD-L1 expression and gene expression profiles
- in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol. **119**, 105368
- 724 (2021).
- 725 37. The Cancer Genome Atlas (TCGA). https://www.cancer.gov/tcga.
- 726 38. Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell
- 727 carcinomas. *Nature* **517**, 576–582 (2015).
- 39. Lohavanichbutr, P. et al. A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and
- 729 External Validation. *Clin. Cancer Res.* **19**, 1197–1203 (2013).
- 40. Brazma, A. *et al.* Minimum information about a microarray experiment (MIAME)—toward
  standards for microarray data. *Nat. Genet.* 29, 365–371 (2001).
- 41. Brazma, A. et al. MINSEQE: Minimum Information about a high-throughput Nucleotide
- 733 SeQuencing Experiment a proposal for standards in functional genomic data reporting. (2012)
- 734 doi:10.5281/zenodo.5706412.
- 42. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th Edition of the
- AJCC Cancer Staging Manual and the Future of TNM. *Ann. Surg. Oncol.* **17**, 1471–1474 (2010).
- 43. Hernández, L. *et al.* HeNeCOn: An ontology for integrative research in Head and Neck cancer.
- 738 Int. J. Med. Inf. **181**, 105284 (2024).
- 44. Nauta, I. H. *et al.* The unveiled reality of human papillomavirus as risk factor for oral cavity
- 740 squamous cell carcinoma. *Int. J. Cancer* **149**, 420–430 (2021).
- 45. Jones, M. & Fowler, R. Immortal time bias in observational studies of time-to-event outcomes. J.
- 742 *Crit. Care* **36**, 195–199 (2016).

- 46. Ness, A. R. *et al.* Establishing a large prospective clinical cohort in people with head and neck
- cancer as a biomedical resource: head and neck 5000. *BMC Cancer* **14**, 973 (2014).
- 47. Ness, A. R. et al. Recruitment, response rates and characteristics of 5511 people enrolled in a
- prospective clinical cohort study: head and neck 5000. *Clin. Otolaryngol.* **41**, 804–809 (2016).
- 48. Mi, X., Hammill, B. G., Curtis, L. H., Lai, E. C.-C. & Setoguchi, S. Use of the landmark method to
- address immortal person-time bias in comparative effectiveness research: a simulation study.
- 749 *Stat. Med.* **35**, 4824–4836 (2016).
- 49. Gleiss, A., Oberbauer, R. & Heinze, G. An unjustified benefit: immortal time bias in the analysis
  of time-dependent events. *Transpl. Int.* **31**, 125–130 (2018).
- 50. Lash, T. L., Fink, A. K. & Fox, M. P. Misclassification. in *Applying Quantitative Bias Analysis to*
- 753 Epidemiologic Data (eds. Lash, T. L., Fox, M. P. & Fink, A. K.) 79–108 (Springer, New York, NY,
- 754 2009). doi:10.1007/978-0-387-87959-8\_6.
- 755 51. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and
  756 microarray studies. *Nucleic Acids Res.* 43, e47 (2015).
- 757 52. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis.
- 758 BMC Bioinformatics **9**, 559 (2008).
- Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using
  empirical Bayes methods. *Biostatistics* 8, 118–127 (2007).
- 54. Zhang, Y., Jenkins, D. F., Manimaran, S. & Johnson, W. E. Alternative empirical Bayes models for
  adjusting for batch effects in genomic studies. *BMC Bioinformatics* **19**, 262 (2018).
- 55. Nygaard, V., Rødland, E. A. & Hovig, E. Methods that remove batch effects while retaining group
- 764 differences may lead to exaggerated confidence in downstream analyses. *Biostatistics* **17**, 29–39
- 765 (2016).
- 56. Carenzo, A. *et al.* hacksig: a unified and tidy R framework to easily compute gene expression
- 767 signature scores. *Bioinformatics* **38**, 2940–2942 (2022).

- 768 57. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for
- 769 Statistical Computing, Vienna, Austria, 2022).
- 58. Mitra, R. et al. Learning from data with structured missingness. Nat. Mach. Intell. 5, 13–23
- 771 (2023).
- 59. Harrell, F. E., Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the Yield of Medical
- 773 Tests. JAMA 247, 2543–2546 (1982).
- 60. Hartman, N., Kim, S., He, K. & Kalbfleisch, J. D. Pitfalls of the concordance index for survival
- 775 outcomes. *Stat. Med.* **42**, 2179–2190 (2023).
- 61. Royston, P. Explained Variation for Survival Models. *Stata J.* 6, 83–96 (2006).
- 62. O'Quigley, J., Xu, R. & Stare, J. Explained randomness in proportional hazards models. *Stat. Med.*
- **24**, 479–489 (2005).
- 63. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination.
- 780 Biometrika **78**, 691–692 (1991).
- 781 64. Shuster, J. J. Median follow-up in clinical trials. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 9, 191–
- 782 192 (1991).
- 783 65. Dai, Y.-H. et al. Radiosensitivity index emerges as a potential biomarker for combined
- radiotherapy and immunotherapy. *Npj Genomic Med.* **6**, 40 (2021).
- 785 66. Torres-Roca, J. F. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based
- personalized radiation therapy. *Pers. Med.* **9**, 547–557 (2012).
- 67. Groenwold, R. H. H. et al. Missing covariate data in clinical research: when and when not to use
- the missing-indicator method for analysis. CMAJ **184**, 1265–1269 (2012).
- 68. Song, M., Zhou, X., Pazaris, M. & Spiegelman, D. The Missing Covariate Indicator Method is
- 790 Nearly Valid Almost Always. Preprint at https://doi.org/10.48550/arXiv.2111.00138 (2021).
- 791 69. Merck. Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck
- 792 Cancer [Press release]. https://www.merckgroup.com/en/news/xevinapant-update.html (2024).

793	70 Lee N V et al Avelumah	hlus standard-of-care chemoradiotheran	versus chemoradiotheranv
/ 55	70. Lee, $N.$ $1.$ et ul. Avelullian	side standard-or-care chemoradiotherapy	versus chemoraulotherapy

- alone in patients with locally advanced squamous cell carcinoma of the head and neck: a
- randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450–
- 796 462 (2021).
- 797 71. Machiels, J.-P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus
- 798 concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of
- the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 25,

800 572–587 (2024).

- 801 72. Mehanna, H. et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-
- 802 positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase
- 803 3 trial. *The Lancet* **393**, 51–60 (2019).
- 804 73. Gillison, M. L. *et al.* Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive
   805 oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority
- trial. *The Lancet* **393**, 40–50 (2019).
- 807 74. Tao, Y. *et al.* Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with
- 808 locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01
- 809 PembroRad): a multicenter, randomized, phase II trial. Ann. Oncol. 34, 101–110 (2023).

810

#### Table 1. Cohort characteristics for head and neck cancer patients used to test the 172-GS and 3 812 clusters HPV signatures. The disease-free survival (DFS) dataset is a subset of the overall survival 813

814

dataset, where patients without data on DFS are excluded.

	Overall survival dataset	Disease-free survival dataset
	(N=1097)	(N=907)
172 06 20010		(11-307)
Maan (CD)	0.0 (1.0)	0.0 (1.0)
Mean (SD)	0.0(1.0)	0.0(1.0)
Median (Min, Max)	0.1 (-4.5, 3.6)	0.1 (-4.9, 3.5)
3 clusters HPV score		
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	0.0 (-2.8, 6.9)	0.0 (-2.9, 3.5)
Study ID		
BD2_INT_MI	310 (28.3%)	310 (34.2%)
BD2_UDUS	127 (11.6%)	127 (14.0%)
GECO110	107 (9.8%)	107 (11.8%)
GSE41613	97 (8.8%)	0 (0%)
SCANDARE	32 (2.9%)	0 (0%)
TCGA	424 (38.7%)	363 (40.0%)
Clinical age at diagnosis		
Mean (SD)	61.0 (11.9)	60.8 (11.7)
Median (Min, Max)	61.0 (19.0, 93.0)	61.0 (19.0, 93.0)
Clinical sex		
Male	794 (72.4%)	660 (72.8%)
Female	303 (27.6%)	247 (27.2%)
Disease extension at diagnosis		( )
Farly disease	161 (14 7%)	98 (10 8%)
Locoregionally advanced disease	936 (85 3%)	809 (89 2%)
	566 (66.676)	000 (00.270)
Orophaniny	227 (20 7%)	218 (24 0%)
Hypophanyny	55 (5.0%)	52 (5 7%)
	165 (15.0%)	JEO (16 5%)
Oral covity	FOS (F4 F9/)	451 (40 7%)
Missing	530(34.376)	431 (49.770) 26 (4.0%)
	52 (4.7%)	30 (4.0%)
	450 (44.00/)	454 (46 60()
Positive	150 (14.2%)	
Negative	941 (85.8%)	756 (83.4%)
Smoking		
Never	230 (21.0%)	213 (23.5%)
Current or Former	653 (59.5%)	609 (67.1%)
Missing	214 (19.5%)	85 (9.4%)
Undergone cancer surgery		
No	187 (17.0%)	187 (20.6%)
Yes	854 (77.8%)	672 (74.1%)
Missing	56 (5.1%)	48 (5.3%)
Radiotherapy treatment		
No	208 (19.0%)	146 (16.1%)
Yes	752 (68.6%)	633 (69.8%)
Missing	137 (12.5%)	128 (14.1%)
Systemic treatment	-	
No	302 (27.5%)	233 (25.7%)
Yes	461 (42.0%)́	426 (47.0%)
Missing	334 (30.4%)	248 (27.3%)

815

#### Table 2. Hazard ratios (HR) of gene signatures and covariates that were tested in interaction 817

with the signatures for head and neck cancer patients. Estimates are from models where 2-818

year overall survival or 2-year disease-free survival was the endpoint and the effect of other 819

clinical covariates were jointly estimated (see Tables S5, S6, S7, S8, S9 for detailed results). 820

Sign stress	Variable	Parameter	<b>Overall survival</b>		Disease-free survival	
Signature			HR [95% CI]	P-value	HR [95% CI]	P-value
	HPV-status	HPV positive	Reference	-	Reference	-
	III v-status	HPV negative	4.27 [2.03, 9.01]	< 0.001	4.43 [2.44, 8.02]	< 0.001
172-GS	Signature score	Score given HPV positive	1.87 [0.61, 5.78]	0.274	1.67 [0.69, 4.05]	0.254
		Score given HPV negative	1.41 [1.25, 1.59]	< 0.001	1.36 [1.17, 1.59]	< 0.001
	HPV_status	HPV positive	Reference	-	Reference	-
	III v-status	HPV negative	4.17 [2.03, 8.57]	< 0.001	4.01 [2.26, 7.14]	< 0.001
3 clusters HPV	Signature score	Score given HPV positive	0.41 [0.24, 0.71]	0.001	0.51 [0.33, 0.77]	0.001
		Score given HPV negative	0.89 [0.77, 1.02]	0.084	1.06 [0.91, 1.23]	0.454
	Dedicthemeny	No	Reference		Reference	
	Radiotherapy	Yes	0.81 [0.54, 1.21]	0.306	1.08 [0.82, 1.42]	0.601
RSI	Signatura saora	Score given radiotherapy = no	1.17 [0.90, 1.52]	0.249	1.01 [0.79, 1.27]	0.929
	Signature score	Score given radiotherapy = yes	1.25 [1.08, 1.44]	0.003	1.08 [0.82, 1.42]	0.306
	~ .	Platinum based	Reference	-	Reference	-
	Systemic	Non-platinum based	0.57 [0.28, 1.15]	0.114	0.94 [0.44, 2.01]	0.873
	шегару	No systemic treatment	1.24 [0.75, 2.04]	0.409	0.97 [0.63, 1.49]	0.882
Pancancer-		Score given systemic therapy = platinum based	1.29 [1.04, 1.59]	0.020	1.23 [0.82, 1.84]	0.316
cispiatin	Signature score	Score given systemic therapy = non-platinum based	0.82 [0.42, 1.59]	0.552	2.00 [0.90, 4.45]	0.089
		Score given systemic therapy = no	1.37 [0.51, 3.69]	0.540	0.92 [0.37, 2.31]	0.862
	Systemic	Cetuximab based	Reference		Reference	
		Non-cetuximab based	1.07 [0.49, 2.31]	0.869	0.71 [0.34, 1.48]	0.363
	unerapy	No systemic treatment	1.22 [0.51, 2.91]	0.657	0.69 [0.31, 1.54]	0.364
Cl3- hypoxia	Signature score	Score given systemic therapy = cetuximab based	0.67 [0.39, 1.14]	0.137	0.61 [0.33, 1.13]	0.114
		Score given systemic therapy = non-cetuximab based	0.69 [0.54, 0.87]	0.002	0.59 [0.44, 0.80]	0.001
		Score given systemic therapy = no	1.70 [1.12, 2.58]	0.013	1.71 [1.14, 2.56]	0.010



824

Figure 1. Exclusion flowchart. The largest number of eligible patients used in the most 825

826 inclusive models (models testing the signatures 172-GS, 3 clusters HPV and RSI with overall survival as the endpoint) is shown. See Figures S1, S2, S3 for exclusion flowcharts for other 827 828 gene signature models.







- survival. a, b Estimated relationship in HPV-positive patients and HPV-negative patients,
  respectively. The signature score is scaled to a mean of 0 and a standard deviation of 1. Note
- the difference in sample size (N) per group. **c**, **d** Distribution of signature values in HPV-
- 835 positive and HPV-negative patients, respectively.
- 836
- 837
- 838
- 839





840



overall survival. a, b Estimated relationship in HPV-positive patients and HPV-negative 842

patients, respectively. The signature score is scaled to a mean of 0 and a standard deviation of 843

1. Note the difference in sample size (N) per group. c, d Distribution of signature values in 844

HPV-positive and HPV-negative patients, respectively. 845





849

850 Figure 4. Estimated relationship between the radiosensitivity index (*RSI*) and 2-year

851 overall survival. a Relationship in patients that did not receive radiotherapy. b Relationship
 852 in patients that received radiotherapy. c Relationship in patients with missing information

in patients that received radiotherapy. **c** Relationship in patients with missing information about radiotherapy treatment. The *RSI* score is scaled to a mean of 0 and a standard deviation

about radiotherapy treatment. The *RSI* score is scaled to a mean of 1. Note the difference in sample size (N) per group.

856



857

858 Figure 5. Estimated relationship between the *pancancer-cisplatin* signature and 2-year overall survival. a Relationship in patients that received platinum-based chemotherapy. b 859 Relationship in patients that received non-platinum based systemic treatment. c Relationship 860 in patients that did not receive systemic treatment. d Relationship in patients with missing 861

information about systemic treatment. The signature score is scaled to a mean of 0 and a 862

standard deviation of 1. Note the difference in sample size (N) per group. 863

865



866

867 Figure 6. Estimated relationship between the *Cl3-hypoxia* signature and 2-year overall

survival. a Relationship in patients that received cetuximab-based treatment. b Relationship 868

in patients that received non-cetuximab based systemic treatment. c Relationship in patients 869

870 that did not receive systemic treatment. d Relationship in patients with missing information about systemic treatment. The signature score is scaled to a mean of 0 and a standard 871

deviation of 1. Note the difference in sample size (N) per group. 872